User profiles for François Bertucci
Francois BertucciProfesseur de Médecine - Institut Paoli-Calmettes - Aix-Marseille Université Verified email at ipc.unicancer.fr Cited by 33562 |
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature
…, J Dutcher, M Brown, P Viens, L Xerri, F Bertucci… - Cancer research, 2009 - AACR
Tumors may be initiated and maintained by a cellular subcomponent that displays stem cell
properties. We have used the expression of aldehyde dehydrogenase as assessed by the …
properties. We have used the expression of aldehyde dehydrogenase as assessed by the …
Aldehyde dehydrogenase 1–Positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer
…, B Esterni, G Houvenaeghel, JM Extra, F Bertucci… - Clinical cancer …, 2010 - AACR
Purpose: To examine the role of cancer stem cells (CSC) in mediating metastasis in
inflammatory breast cancer (IBC) and the association of these cells with patient outcome in this …
inflammatory breast cancer (IBC) and the association of these cells with patient outcome in this …
How basal are triple‐negative breast cancers?
F Bertucci, P Finetti, N Cervera, B Esterni… - … journal of Cancer, 2008 - Wiley Online Library
The basal molecular subtype of breast cancer (BC) is defined by the mRNA expression
pattern of an intrinsic ∼500‐gene set. It is the most homogeneous subtype in transcriptional …
pattern of an intrinsic ∼500‐gene set. It is the most homogeneous subtype in transcriptional …
Genomic characterization of metastatic breast cancers
Metastasis is the main cause of death for patients with breast cancer. Many studies have
characterized the genomic landscape of breast cancer during its early stages. However, there is …
characterized the genomic landscape of breast cancer during its early stages. However, there is …
[HTML][HTML] Prognostic and predictive value of PDL1 expression in breast cancer
Expression of programmed cell death receptor ligand 1 (PDL1) has been scarcely studied
in breast cancer. Recently PD1/PDL1-inhibitors have shown promising results in different …
in breast cancer. Recently PD1/PDL1-inhibitors have shown promising results in different …
[PDF][PDF] Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets
…, LW Guo, YC Pei, WJ Chai, DQ Li, F Bai, F Bertucci… - Cell metabolism, 2021 - cell.com
Triple-negative breast cancer (TNBC) remains an unmet medical challenge. We investigated
metabolic dysregulation in TNBCs by using our multi-omics database (n = 465, the largest …
metabolic dysregulation in TNBCs by using our multi-omics database (n = 465, the largest …
Integrated profiling of basal and luminal breast cancers
…, P Viens, J Jacquemier, D Birnbaum, F Bertucci… - Cancer research, 2007 - AACR
Basal and luminal are two molecular subtypes of breast cancer with opposite histoclinical
features. We report a combined, high-resolution analysis of genome copy number and gene …
features. We report a combined, high-resolution analysis of genome copy number and gene …
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial
…, BN Bui, A Adenis, M Rios, F Bertucci… - The lancet …, 2010 - thelancet.com
Background The effect of imatinib discontinuation on progression-free survival and overall
survival in long-lasting responders with advanced gastrointestinal stromal tumours (GIST) is …
survival in long-lasting responders with advanced gastrointestinal stromal tumours (GIST) is …
Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
…, L Jiang, LP Ge, SY Wu, Q Yu, Q Zhang, F Bertucci… - Cell research, 2022 - nature.com
Metabolic reprogramming is a hallmark of cancer. However, systematic characterizations of
metabolites in triple-negative breast cancer (TNBC) are still lacking. Our study profiled the …
metabolites in triple-negative breast cancer (TNBC) are still lacking. Our study profiled the …
[HTML][HTML] Improved survival using specialized multidisciplinary board in sarcoma patients
…, F Gouin, JE Kurtz, C Lebbe, N Isambert, F Bertucci… - Annals of …, 2017 - Elsevier
Background Sarcomas are rare but aggressive diseases. Specialized multidisciplinary
management is not implemented for all patients in most countries. We investigated the impact of a …
management is not implemented for all patients in most countries. We investigated the impact of a …